9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 101–200 of 975
Narváez, J. J. U., & Campos, M. R. S. (2021) · Journal of Food Science · doi:10.1111/1750-3841.15939 · Cited by 65
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Bušek, P., Duke‐Cohan, J. S., & Šedo, A. (2022) · Cancers · doi:10.3390/cancers14092072 · Cited by 58
Rudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108931 · Cited by 46
Alenzi, K. A. O., Alsuhaibani, D. S., Batarfi, B. S., & Alshammari, T. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364110 · Cited by 52
“GLP-1 RAs or sodium-dependent glucose transporter 2 (SGLT2) inhibitors are often recommended for patients with T2DM who have atherosclerotic cardiovascular disease (ASCVD) or indicators of high risk for it due to the cardiovascular bene fi ts they provide (American Diabetes Association, 2021).”
BackgroundDornbos, P., Koesterer, R., Ruttenburg, A., Nguyen, T., Cole, J. B., AMP-T2D-GENES Consortium, Leong, A., Meigs, J. B., Florez, J. C., Rotter, J. I., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01200-1 · Cited by 46
Advances of microneedles in hormone delivery
Nguyen, T. T., Nguyen, T. T. D., An, T. N. M., & Vo, G. V. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112393 · Cited by 49
Kawai, Y., Uneda, K., Yamada, T., Kinguchi, S., Kobayashi, K., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109146 · Cited by 49
Segar, M. W., Kolkailah, A. A., Frederich, R. C., Pong, A., Cannon, C. P., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Liu, C., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14769 · Cited by 44
Teague, T., Payne, S. R., Kelly, B. T., Dempsey, T. M., McCoy, R. G., Sangaralingham, L. R., & LIMPER, A. H. (2022) · Respiratory Research · doi:10.1186/s12931-022-02001-0 · Cited by 56
Shin, H., Schneeweiß, S., Glynn, R. J., & Patorno, E. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4012 · Cited by 48
Mannucci, E., Gallo, M., Giaccari, A., Candido, R., Pintaudi, B., Targher, G., Monami, M., & Diabetes, T. S. J. P. F. I. G. O. T. O. T. 2. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14888 · Cited by 43
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021) · Medicina · doi:10.3390/medicina57070669 · Cited by 43
Boye, K. S., Lage, M. J., Thieu, V. T., Shinde, S., Dhamija, S., & Bae, J. P. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107975 · Cited by 52
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Zhou, X., Ye, X., Guo, X., Liu, D., Xu, J., Hu, F., Zhai, Y., Gao, Y., Xu, X., Dong, Z., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.766125 · Cited by 49
“In both SGLT2i-induced AEs and IMEs, we obtained signals of infectious, metabolic, and urinary/renal events, which was generally consistent with the safety data obtained from RCTs (Scheen, 2019; American Diabetes, 2021).”
BackgroundResultEffects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
Wang, D., Liu, J. Y., Zhou, L., Zhang, Q., Li, M., & Xiao, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.905171 · Cited by 52
Khunti, K., Jabbour, S. A., Cos, X., Mudaliar, S. R. D., Mende, C. W., Bonaca, M. P., & Fioretto, P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14684 · Cited by 45
Post-transplant diabetes mellitus following heart transplantation
Newman, J. D., Schlendorf, K. H., Cox, Z. L., ZALAWADIYA, S. K., Powers, A. C., Niswender, K. D., Shah, R. V., & Lindenfeld, J. M. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.07.011 · Cited by 49
Caturano, A., Galiero, R., Loffredo, G., Vetrano, E., Medicamento, G., Acierno, C., Rinaldi, L., Marrone, A., Salvatore, T., Monda, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020322 · Cited by 44
Is there a role for glucagon‐like peptide‐1 receptor agonists in the treatment of male infertility?
Cannarella, R., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2021) · Andrology · doi:10.1111/andr.13015 · Cited by 60
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Cahn, A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Murphy, S. A., Yanuv, I., Rozenberg, A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1744 · Cited by 45
Beavers, K. M., Cortes, T. M., Foy, C. M., Dinkla, L., Reyes San Martin, F., Ard, J. D., Serra, M. C., & Beavers, D. P. (2025) · Obesity · doi:10.1002/oby.24172 · Cited by 41
Mata‐Cases, M., Vlacho, B., Real, J., Puig-Treserra, R., Bundó, M., Franch‐Nadal, J., & Mauricio, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.810757 · Cited by 46
Bitirim, C. V., Aksoy, Z. B., Aydos, D., Genc, K., Demirsoy, Ş., Akçalı, K. C., & Turan, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-09627-6 · Cited by 42
Cohen, R. V., Pereira, T. V., Aboud, C. M., Zanata Petry, T. B., Lopes Correa, J. L., Schiavon, C. A., Pompílio, C. E., Quirino Pechy, F. N., Calmon da Costa Silva, A. C., Cunha da Silveira, L. P., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101725 · Cited by 41
Janež, A., Muzurović, E. M., Stoian, A. P., Haluzík, M., Guja, C., Czupryniak, L., Duvnjak, L. S., Lalic, N. M., Tankova, T. I., Bogdański, P., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.017 · Cited by 43
Obafemi, T. O., Jaiyesimi, K. F., Olomola, A. A., Olasehinde, O. R., Olaoye, O. A., Adewumi, F. D., Afolabi, B. A., Adewale, O. B., Akintayo, C. O., & Ojo, O. A. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.07.011 · Cited by 43
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
Giugliano, D., Scappaticcio, L., Longo, M., Bellastella, G., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01400-9 · Cited by 40
Whiteson, J. H., Azola, A. M., Barry, J. T., Bartels, M. N., Blitshteyn, S., Fleming, T. K., McCauley, M. D., Neal, J. D., Pillarisetti, J., Sampsel, S., et al. (2022) · PM&R · doi:10.1002/pmrj.12859 · Cited by 43
Zhuo, M., D’Andrea, E., Paik, J. M., Wexler, D. J., Everett, B. M., Glynn, R. J., Kim, S. C., & Patorno, E. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.35995 · Cited by 43
Berget, C., Sherr, J. L., DeSalvo, D. J., KINGMAN, R. S., Stone, S. L., Brown, S. A., Nguyen, A., Barrett, L., Ly, T. T., & Forlenza, G. P. (2022) · Clinical Diabetes · doi:10.2337/cd21-0083 · Cited by 42
Chubb, B., Gupta, P., Gupta, J., Nuhoho, S., Kallenbach, K., & Orme, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01034-w · Cited by 39
Perioperative glycemic management in adults presenting for elective cardiac and non-cardiac surgery
Sreedharan, R., Khanna, S. K., & Shaw, A. (2023) · Perioperative Medicine · doi:10.1186/s13741-023-00302-6 · Cited by 70
Chen, Y., Yang, Z., Liu, Y., Gue, Y. X., Zhong, Z., Chen, T., Wang, F., McDowell, G., Huang, B., & Lip, G. Y. H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02521-7 · Cited by 39
“This suggests that the impact of GV during the initial phase may be diminished by early interventions and acute management strategies commonly employed in DM patients, such as insulin treatment [44].”
Intersection Between Chronic Kidney Disease and Cardiovascular Disease
Laffin, L. J., & Bakris, G. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01546-8 · Cited by 50
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
Theurey, P., Vial, G., Fontaine, E. M., Monternier, P., Fouqueray, P., Bolze, S., Moller, D. E., & Hallakou‐Bozec, S. (2022) · Physiological Reports · doi:10.14814/phy2.15151 · Cited by 44
“Despite a common chemical moiety, it is not classified as biguanide by the WHO; rather, it is classified as “Other Drugs Used in Diabetes” (WHO ATC Code A10B- X15).”
Aroda, V. R., Bauer, R., Christiansen, E., Haluzík, M., Kallenbach, K., Montanya, E., Rosenstock, J., & Meier, J. J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14710 · Cited by 38
Perioperative Management of a Patient With Cushing Disease
Varlamov, E. V., Vila, G., & Fleseriu, M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac010 · Cited by 41
Fried, L. F., Schmedt, N., Folkerts, K., Bowrin, K., Raad, H., Batech, M., & Kovesdy, C. P. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac140 · Cited by 45
Race/ethnicity and challenges for optimal insulin therapy
do Vale Moreira, N. C., Ceriello, A., Basit, A., Balde, N., Mohan, V., Gupta, R., Misra, A., Bhowmik, B., Lee, M. K., Zuo, H., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108823 · Cited by 37
Tanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01295-6 · Cited by 37
Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations
Klen, J., & Dolžan, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189800 · Cited by 47
Erectile dysfunction as a marker of endocrine and glycemic disorders
Mazzilli, R., Zamponi, V., Olana, S., Mikovic, N., Cimadomo, D., Defeudis, G., & Faggiano, A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01788-5 · Cited by 52
Yang, A., Wu, H., Lau, E. S. H., Zhang, X., Shi, M., Fan, B., Ronald, C. W., Kong, A. P. S., Luk, A. O. Y., Chan, J. C. N., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100509 · Cited by 44
Ekberg, N. R., Hartvig, N. V., Kaas, A., Møller, J. B., & Adolfsson, P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221104142 · Cited by 36
Metabolic Consequences of Antiretroviral Therapy
Diggins, C. E., Russo, S. C., & Lo, J. (2022) · Current HIV/AIDS Reports · doi:10.1007/s11904-022-00600-6 · Cited by 43
Nair, R., Mody, R., Yu, M. B., Cowburn, S., Кониг, М., & PREWITT, T. G. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01320-1 · Cited by 39
Cahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Bhatt, D. L., McGuire, D. K., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2492 · Cited by 44
Rao, S. D. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01989-z · Cited by 46
A Century-long Journey From the Discovery of Insulin to the Implantation of Stem Cell–derived Islets
Ramzy, A., Belmonte, P. J., Braam, M. J. S., Ida, S., Wilts, E. M., Levings, M. K., Rezania, A., & Kieffer, T. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac021 · Cited by 34
Hao, R. C., Myroniuk, T. W., McGuckin, T., Manca, D. P., Campbell-Scherer, D. L., Lau, D., & Yeung, R. O. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01731-w · Cited by 41
McDaniel, C. C., Kavookjian, J., & Whitley, H. P. (2022) · Patient Education and Counseling · doi:10.1016/j.pec.2021.07.036 · Cited by 35
Update on prevention of diabetic foot ulcer
Miranda, C., ROS, R. D., & Marfella, R. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.107817 · Cited by 59
Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms
Ahmadi, A., Panahi, Y., Johnston, T. P., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105819 · Cited by 39
Wong, C., Dash, A., Fredrickson, J. O., Lewin‐Koh, N., Chen, S., Yoshida, K. J., Liu, Y., Gutierrez, J., & Kunder, R. S. (2022) · Hepatology · doi:10.1002/hep.32742 · Cited by 38
“[2,3] Despite maintenance of glycemic targets via lifestyle changes and pharmacologic monotherapy, most patients with T2DM will progress, requiring combination therapy, and, ultimately, injectable therapy including insulin.[4] As there is currently no Food and Drug Administration–approved pharmaceutical therapy for NA…”
BackgroundTye, S. C., Jongs, N., Coca, S. G., Sundström, J., Arnott, C. G., Neal, B. C., Perkovic, V., Mahaffey, K. W., Vart, P., & Heerspink, H. J. L. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01619-0 · Cited by 35
Formichi, C., Fignani, D., Nigi, L., Grieco, G. E., Brusco, N., Licata, G., Sabato, C., Ferretti, E., Sebastiani, G., & Dotta, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179454 · Cited by 38
Sim, R., Chong, C. W., Loganadan, N. K., Fong, A. Y. Y., Navaravong, L., Hussein, Z. B., Khunti, K., & Lee, S. W. H. (2021) · Diabetic Medicine · doi:10.1111/dme.14780 · Cited by 37
Managing Patients Undergoing Orthopedic Surgery to Improve Glycemic Outcomes
Díaz, R. S., & DeJesus, J. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01434-z · Cited by 36
Big data and machine learning to tackle diabetes management
Pina, A. F., Meneses, M. J., Sousa‐Lima, I., Henriques, R., Raposo, J. F., & Macedo, M. P. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13890 · Cited by 40
The Evolution of Hypertension Guidelines Over the Last 20+ Years: A Comprehensive Review
Evbayekha, E. O., Okobi, O. E., Okobi, T., Ibeson, E. C., Nwafor, J. N., Ozobokeme, O.-E., Olawoye, A., Ngoladi, I. A., Boms, M. G., Habib, F. A., et al. (2022) · Cureus · doi:10.7759/cureus.31437 · Cited by 50
Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
Torun, A., Hupalowska, A., Trzonkowski, P., Kierkuś, J., & Pyrzyńska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642166 · Cited by 42
Saffo, S., Kaplan, D. E., Mahmud, N., Serper, M., John, B. V., Ross, J. S., & Taddei, T. H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14488 · Cited by 39
Cefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., & Rosenblum, N. D. (2021) · Diabetes Care · doi:10.2337/dci21-0051 · Cited by 40
Tian, J., Si, X., Shu, C., Wang, Y., Tan, H., Zang, Z., Zhang, W., Xie, X., Chen, Y., & Li, B. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07799 · Cited by 37
Qi, M., Santos, H., da Silva, P. P., McGuinness, D. L., & Bennett, K. P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290692 · Cited by 51
Shin, J., Wang, D., Fernandes, G. F., Daya, N. R., Grams, M. E., Golden, S. H., Rajpathak, S. N., & Selvin, E. (2021) · Diabetes Care · doi:10.2337/dc20-2541 · Cited by 34
Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients
Brodosi, L., Petta, S., Petroni, M. L., Marchesini, G., & Morelli, M. C. (2021) · Transplantation · doi:10.1097/tp.0000000000003867 · Cited by 36
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes
Stanton, A. M., Vaduganathan, M., Chang, L., Turchin, A., Januzzi, J. L., & Aroda, V. R. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01407-2 · Cited by 37
Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias
Tahmi, M., & Luchsinger, J. A. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.113 · Cited by 37
Lautsch, D., Boggs, R. L., Wang, T., González, C. D., Milligan, G., Rajpathak, S. N., Malkani, S., McLeod, E. J., Carroll, J., & Higgins, V. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01985-3 · Cited by 47
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Sharma, A., Virmani, T., Sharma, A., Chhabra, V., Kumar, G., Pathak, K., & Alhalmi, A. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s369712 · Cited by 36
Engström, A., Wintzell, V., Melbye, M., Hviid, A. P., Eliasson, B., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Svanström, H., Pasternak, B., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0714 · Cited by 30
Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s312527 · Cited by 30
Ku, E. J., Lee, D., Jeon, H. J., & Oh, T. K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109123 · Cited by 38
Needle Technology for Insulin Administration: A Century of Innovation
Heinemann, L., Nguyen, T. T., Bailey, T. S., Hassoun, A. A. K., Kulzer, B., Oliveria, T., Reznik, Y., de Valk, H. W., & Mader, J. K. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211059564 · Cited by 35
Mathew, B. K., Roza, J. G. D., Liu, C., Goh, L. J., Ooi, C. W., Chen, E., Poon, S., & Tang, W. E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s344607 · Cited by 38
Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes
Lu, S., Yin, H., Yu, O. H. Y., & Azoulay, L. (2022) · Epidemiology · doi:10.1097/ede.0000000000001486 · Cited by 34
Chow, E., Yang, A., Chung, C. H. L., & Chan, J. C. N. (2022) · Pharmaceuticals · doi:10.3390/ph15040442 · Cited by 35
Zhou, K., Zi, X., Song, J., Zhao, Q., Liu, J., Bao, H., & Li, L. (2022) · Molecules · doi:10.3390/molecules27196221 · Cited by 34
Nozawa, K., Ikeda, M., & Kikuchi, S. (2022) · Drugs - Real World Outcomes · doi:10.1007/s40801-022-00309-3 · Cited by 51
Koto, R., Nakajima, A., Miwa, T., & Sugimoto, K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01421-5 · Cited by 33
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
Sarkar, S., Heyward, J., Alexander, G. C., & Kalyani, R. R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.28782 · Cited by 34
Shao, S., Chang, K., Lin, S., Chang, S., Hung, M., Chan, Y., & Lai, E. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01406-3 · Cited by 29
Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
Longo, M., Scappaticcio, L., Cirillo, P., Maio, A., Carotenuto, R. M., Maiorino, M. I., Bellastella, G., & Esposito, K. (2022) · Biomolecules · doi:10.3390/biom12020272 · Cited by 34
Baek, J. H., Yang, Y., Ko, S., Han, K., Kim, J. H., Moon, M. K., Park, J. S., Lee, B., Oh, T. J., Chon, S., et al. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0002 · Cited by 33
Luzuriaga, M., Leite, R. O., Ahmed, H., Saab, P. G., & Garg, R. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002348 · Cited by 36
Abrilla, A. A., Pajes, A. N. N. I., & Jimeno, C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108824 · Cited by 31
Peralta, F. G., Al‐Ozairi, E., Jude, E. B., Li, X., & Rosenstock, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14365 · Cited by 29
Bexagliflozin for type 2 diabetes: an overview of the data
Azzam, O., Carnagarin, R., Lugo‐Gavidia, L. M., Nolde, J. M., Matthews, V. B., & Schlaich, M. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1959915 · Cited by 31
Lee, K. A., Jin, H. Y., Kim, Y. J., Im, Y., Kim, E., & Park, T. S. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e230 · Cited by 29
Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes
Lane, W. S., Lambert, E., George, J., Rathor, N., & Thalange, N. K. S. (2021) · Clinical Diabetes · doi:10.2337/cd20-0117 · Cited by 31
Milder, T. Y., STOCKER, S. L., Baysari, M. T., Day, R. O., & Greenfield, J. R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109036 · Cited by 30
Friedreich’s Ataxia related Diabetes: Epidemiology and management practices
Tamaroff, J. G., Dedio, A., Wade, K., Wells, M., Park, C. C., Leavens, K. F., Rummey, C., Kelly, A. T., Lynch, D. R., & McCormack, S. E. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109828 · Cited by 34
McCrimmon, R. J., Sifri, S. A., Emral, R., Mohan, V., Sauque‐Reyna, L., Trescolí, C., Lalic, N. M., Alvarez, A., Demil, N., Coudert, M., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14354 · Cited by 31
Kibirige, D., Chamba, N. G., Biraro, I. A., Kilonzo, K., Laizer, S. N., Sekitoleko, I., Kyazze, A. P., Ninsiima, S., Ssekamatte, P., Bongomin, F., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060786 · Cited by 34
Representation and Extrapolation: Evidence from Clinical Trials
Alsan, M. M., Durvasula, M., Gupta, H., Schwartzstein, J., & Williams, H. (2023) · The Quarterly Journal of Economics · doi:10.1093/qje/qjad036 · Cited by 50
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.